Navigation Links
Jazz Pharmaceuticals to Present at Investor Conferences
Date:5/16/2008

PALO ALTO, Calif., May 16 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that Robert M. Myers, the company's President, will provide a corporate presentation at two upcoming investor conferences.

Mr. Myers will speak at the UBS Global Specialty and Generic Pharmaceuticals Conference in London at 9:30 a.m. BST (4:30 a.m. EDT) on Wednesday, May 28, 2008.

On Thursday, May 29, 2008 Mr. Myers will present at the FBR Capital Markets Spring Investor Conference in New York City at 8:15 a.m. EDT.

A live webcast of the presentations may be accessed by visiting the Investors section of the Jazz Pharmaceuticals website at http://www.JazzPharmaceuticals.com. A replay will be available on Jazz Pharmaceuticals' website for two weeks following each presentation.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008
2. Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality
3. AMDL Subsidiary Donates Pharmaceuticals in China Earthquake Relief Effort
4. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
5. MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
6. Ferring Pharmaceuticals EUFLEXXA(R) to Serve as a Sponsor for the Babolat World Tennis Classic
7. Sunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. MAP Pharmaceuticals Reports First Quarter of 2008 Financial Results
9. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
10. Vion Pharmaceuticals to Appeal Nasdaq Delisting
11. Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology: